Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum.

Autor:	Bukata SV; Department of Orthopedic Surgery, UCLA Health System, Los Angeles, CA., Blay JY; Department of Medicine, Centre Léon Bérard Cancer Center & Université Claude Bernard Lyon, Lyon, France., Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland., Skubitz K; University of Minnesota, Minneapolis, MN., Henshaw R; Georgetown University and MedStar Washington Cancer Institute, Washington, DC., Seeger L; UCLA Health System, Los Angeles, CA., Dai T; Amgen Inc., Thousand Oaks, CA., Jandial D; Amgen Inc., Thousand Oaks, CA., Chawla S; Sarcoma Oncology Center, Santa Monica, CA.
Jazyk:	angličtina
Zdroj:	Spine [Spine (Phila Pa 1976)] 2021 Mar 01; Vol. 46 (5), pp. 277-284.
DOI:	10.1097/BRS.0000000000003728
Abstrakt:	Study Design: This was a subanalysis of an international, multicenter, open-label study. Objective: The aim of this study was to assess the efficacy and safety of denosumab in a subset of patients with giant cell tumors of bone (GCTB) of the spine including the sacrum from an international, open-label, single-arm, phase 2 study (ClinicalTrials.gov: NCT00680992). Summary of Background Data: Standard GCTB treatment is surgical removal, either by curettage or resection, combined with intraoperative adjuvant therapy; however, some sites may not be amenable to resection (e.g., skull, spine). Methods: Adults or skeletally mature adolescents with pathologically confirmed GCTB of the spine including the sacrum, and radiologically measurable evidence of active disease, were included. Patients received denosumab (120 mg subcutaneously) once every 4 weeks during the treatment phase, with loading doses on days 8 and 15 of the first cycle. Patients had surgically unsalvageable GCTB (Cohort 1), had planned surgery expected to result in severe morbidity (Cohort 2), or were enrolled from a previous GCTB study (Cohort 3). Results: Overall, 132 patients were included in the safety analysis (103 in Cohort 1, 24 in Cohort 2, and five in Cohort 3); 131 patients were included in the efficacy analysis. Kaplan-Meier estimated probabilities of disease progression or recurrence were 3% (95% confidence interval [CI], 0.0-6.2) at year 1 and 7.4% (95% CI, 2.1-12.7) at years 3 and 5 in Cohort 1, and not estimable in Cohorts 2 and 3. Of 23 patients (Cohort 2) with surgery planned at baseline, 10 (43%) had on-study surgery; of these, one patient had reported disease progression or recurrence after the on-study surgery. Clinical benefit was reported in 83% of patients overall (all cohorts). Conclusion: Results from the analysis suggest that denosumab is potentially effective treatment for patients with GCTB of the spine including the sacrum. The adverse event profile was consistent with the full study population.Level of Evidence: 2. (Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu